Bridging the Divide When Neither Drug Nor Device is Enough
Hosted by MDG Boston, April 7, 2021.
Successful commercialization of combination products is an exciting, profitable arena for innovative concepts. Many significant advances in disease treatment come from combination products, which enable delivery of drugs in a more precise, controlled manner. But how to do it right?
This MDG forum brought together a panel of experts to discuss how to deliver combination products that bridge the divide when neither a drug or a device alone is enough.
Elazer R. Edelman, Director, Institute of Medical Engineering Engineering, and Science Director, Clinical Research Center at MIT; current occupant of the Edward J. Poitras Chair as Professor of Medical Engineering and Science
"Combinatorial Communities" (3:49)
John D. McDermott, Jr, MBA, Senior Director, Reimbursement Strategy, MCRA
“Considerations for Reimbursement for Combination Products” (24:33)
Tony Voiers, CEO, Advanced Chemotherapy Technologies (ACT)
"Combination Products in the Treatment of Pancreatic Cancer: A firsthand account of the challenges unique to early-stage combination product companies” (12:28)
Michael John, VP, Cardiovascular Regulatory Affairs at MCRA and former Chief, Interventional CV Devices Branch, Division of CV Devices, FDA
“FDA Regulation of Combination Products: An Insider's View” (11:25)